Head to Head Survey: Cingulate (NASDAQ:CING) vs. Qiagen (NYSE:QGEN)

Cingulate (NASDAQ:CING) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Cingulate and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
Qiagen	20.33%	14.56%	8.62%

Earnings & Valuation

This table compares Cingulate and Qiagen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45 million	($4.32)	-1.19
Qiagen	$2.09 billion	3.41	$424.88 million	$2.02	17.12

Qiagen has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Cingulate and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1	0	2	0	2.33
Qiagen	1	6	4	1	2.42

Cingulate presently has a consensus target price of $34.50, suggesting a potential upside of 569.90%. Qiagen has a consensus target price of $47.09, suggesting a potential upside of 36.17%. Given Cingulate’s higher probable upside, equities research analysts clearly believe Cingulate is more favorable than Qiagen.

Volatility & Risk

Cingulate has a beta of -0.76, suggesting that its share price is 176% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Qiagen beats Cingulate on 13 of the 14 factors compared between the two stocks.

About Cingulate

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.